NGAL bryder igennem i 2013

Skal man tro Bioportos egne distributører så bliver 2013 året hvor NGAL salget starter op for alvor.

Bioporto har netop afholdte NGAL distributør forum, hvor en række meget interessante mennesker deltog, og hvor den ene af dem kaldte det en ,”no brainer” at benytte NGAL testen som eksklusionstest.

Det egentlig burde få en tråd selv  men istedet vil jeg springe til en række andre ting fra mødet.

Lad os starte med citatet så jeg ikke fejlfortolker noget:

“The NGAL Test™ distributor LabMark came to the meeting with the long awaited news that reimbursement for NGAL will be a reality from 2013 in the Czech Republic. Reimbursement has been debated for the past two years by the Czech health authorities and this recent decision makes the Czech Republic the first country in the world to open reimbursement for NGAL.” 1

Jamen så siger vi tak til Tjekkiet og LabMark som bidrog ydereligere til festen:

“LabMark also shared information about their excellent collaboration with Roche in Czech about promoting The NGAL Test™ together. We believe that this is a great opportunity to reach the customers of a major instrument provider.”

Og endelig åbnede en (hvad jeg formoder må være en) amerikansk distributør champagneflaskerne med denne nyhed:

“Another distributor shared that they have won a tender for providing a high number of NGAL tests to a Clinical Research Organization (CRO) working on a clinical trial for a major pharmaceutical company. The study protocol includes the use of NGAL for toxicology evaluation. The key thing is that this protocol is approved by the FDA, hence recognizing the use of NGAL as a safety biomarker in clinical studies. The distributor is very excited because they expect similar opportunities to arise in the near future.”

2013. NGAL to the metal.

Nå, nu skal jeg jo ikke tage æren for det, så her er det officielle dokument fra Bioporto:

http://ngal.com/news/the-ngal-test%E2%84%A2-distributor-forum-2012/